OBJECTIVE: Multiple system atrophy (MSA), the most common of the atypical parkinsonian disorders, is characterized by the presence of an abnormal spatial covariance pattern in resting state metabolic brain images from patients with this disease. Nonetheless, the potential utility of this pattern as a MSA biomarker is contingent upon its specificity for this disorder and its relationship to clinical disability in individual patients. METHODS: We used [(18)F]fluorodeoxyglucose PET to study 33 patients with MSA, 20 age- and severity-matched patients with idiopathic Parkinson disease (PD), and 15 healthy volunteers. For each subject, we computed the expression of the previously characterized metabolic covariance patterns for MSA and PD (termed MSARP and PDRP, respectively) on a prospective single-case basis. The resulting network values for the individual patients were correlated with clinical motor ratings and disease duration. RESULTS: In the MSA group, disease-related pattern (MSARP) values were elevated relative to the control and PD groups (p < 0.001 for both comparisons). In this group, MSARP values correlated with clinical ratings of motor disability (r = 0.57, p = 0.0008) and with disease duration (r = -0.376, p = 0.03). By contrast, MSARP expression in the PD group did not differ from control values (p = 1.0). In this group, motor ratings correlated with PDRP (r = 0.60, p = 0.006) but not with MSARP values (p = 0.88). CONCLUSIONS: MSA is associated with elevated expression of a specific disease-related metabolic pattern. Moreover, differences in the expression of this pattern in patients with MSA correlate with clinical disability. The findings suggest that the MSARP may be a useful biomarker in trials of new therapies for this disorder.
OBJECTIVE:Multiple system atrophy (MSA), the most common of the atypical parkinsonian disorders, is characterized by the presence of an abnormal spatial covariance pattern in resting state metabolic brain images from patients with this disease. Nonetheless, the potential utility of this pattern as a MSA biomarker is contingent upon its specificity for this disorder and its relationship to clinical disability in individual patients. METHODS: We used [(18)F]fluorodeoxyglucose PET to study 33 patients with MSA, 20 age- and severity-matched patients with idiopathic Parkinson disease (PD), and 15 healthy volunteers. For each subject, we computed the expression of the previously characterized metabolic covariance patterns for MSA and PD (termed MSARP and PDRP, respectively) on a prospective single-case basis. The resulting network values for the individual patients were correlated with clinical motor ratings and disease duration. RESULTS: In the MSA group, disease-related pattern (MSARP) values were elevated relative to the control and PD groups (p < 0.001 for both comparisons). In this group, MSARP values correlated with clinical ratings of motor disability (r = 0.57, p = 0.0008) and with disease duration (r = -0.376, p = 0.03). By contrast, MSARP expression in the PD group did not differ from control values (p = 1.0). In this group, motor ratings correlated with PDRP (r = 0.60, p = 0.006) but not with MSARP values (p = 0.88). CONCLUSIONS: MSA is associated with elevated expression of a specific disease-related metabolic pattern. Moreover, differences in the expression of this pattern in patients with MSA correlate with clinical disability. The findings suggest that the MSARP may be a useful biomarker in trials of new therapies for this disorder.
Authors: J R Moeller; T Nakamura; M J Mentis; V Dhawan; P Spetsieres; A Antonini; J Missimer; K L Leenders; D Eidelberg Journal: J Nucl Med Date: 1999-08 Impact factor: 10.057
Authors: Klaus Seppi; Farid Yekhlef; Anja Diem; Elisabeth Luginger Wolf; Joerg Mueller; François Tison; Niall P Quinn; Werner Poewe; Gregor K Wenning Journal: J Neurol Date: 2005-01 Impact factor: 4.849
Authors: Thomas Eckert; Anna Barnes; Vijay Dhawan; Steve Frucht; Mark F Gordon; Andrew S Feigin; D Eidelberg Journal: Neuroimage Date: 2005-04-26 Impact factor: 6.556
Authors: Felix Geser; Gregor K Wenning; Klaus Seppi; Michaela Stampfer-Kountchev; Christoph Scherfler; Martin Sawires; Carolin Frick; Jean-Pierre Ndayisaba; Hanno Ulmer; Maria T Pellecchia; Paolo Barone; Hee T Kim; Juzar Hooker; Niall P Quinn; Adriana Cardozo; Eduardo Tolosa; Michael Abele; Thomas Klockgether; Karen Østergaard; Erik Dupont; Nicole Schimke; Karla M Eggert; Wolfgang Oertel; Ruth Djaldetti; Werner Poewe Journal: Mov Disord Date: 2006-02 Impact factor: 10.338
Authors: I Litvan; C G Goetz; J Jankovic; G K Wenning; V Booth; J J Bartko; A McKee; K Jellinger; E C Lai; J P Brandel; M Verny; K R Chaudhuri; R K Pearce; Y Agid Journal: Arch Neurol Date: 1997-08
Authors: D Eidelberg; S Takikawa; J R Moeller; V Dhawan; K Redington; T Chaly; W Robeson; J R Dahl; D Margouleff; E Fazzini Journal: Ann Neurol Date: 1993-05 Impact factor: 10.422
Authors: Tetsutaro Ozawa; Dominic Paviour; Niall P Quinn; Keith A Josephs; Hardev Sangha; Linda Kilford; Daniel G Healy; Nick W Wood; Andrew J Lees; Janice L Holton; Tamas Revesz Journal: Brain Date: 2004-10-27 Impact factor: 13.501
Authors: Florian Holtbernd; Jean-François Gagnon; Ron B Postuma; Yilong Ma; Chris C Tang; Andrew Feigin; Vijay Dhawan; Mélanie Vendette; Jean-Paul Soucy; David Eidelberg; Jacques Montplaisir Journal: Neurology Date: 2014-01-22 Impact factor: 9.910